Previously, when we examined concentrations of IGF axis analytes in serum of subjects in relation to prostate cancer risk in the PCPT, IGFBP-2 was found associated with increased risk for prostate cancer in the placebo arm [23]. The gene discussed is IGF1; the disease is prostate carcinoma.